Novartis | NOVN - Créances Commerciales





Créances Commerciales Changement Date
AbbVie USD 12.59B 180M 2025-12
Alcon AG USD 2.01B 525M 2026-03
Almirall EUR 175.93M 17.87M 2025-12
Amgen USD 9.14B 432M 2026-03
AstraZeneca USD 17.88B 1.17B 2026-03
Autolus Therapeutics Ltd USD 38.07M 37.71M 2026-03
Bayer EUR 18.55B 4.36B 2026-03
Biogen USD 1.79B 76.6M 2026-03
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Eli Lilly USD 21.18B 1.02B 2026-03
Fresenius EUR 3.78B 299M 2025-12
Fresenius Medical Care EUR 3.72B 58.09M 2026-03
Genmab DKK 1.17B 119M 2025-12
Gilead Sciences USD 4.74B 172M 2026-03
GlaxoSmithKline GBP 7.94B 178M 2026-03
GRIFOLS EUR 958M 106M 2026-03
Hikma Pharmaceutical USD 1.08B 27M 2025-12
J&J USD 21.33B 3.72B 2025-12
Lakefront Biotherapeutics EUR 54.03M 145.72M 2026-03
Lonza CHF 1.78B 55M 2025-12
Merck EUR 4.81B 373M 2026-03
Merck USD 11.78B 345M 2025-12
Novartis USD 9.6B 2.69B 2026-03
Novartis USD 12.29B 3.3B 2025-12
Novo Nordisk DKK 106.26B 11.21B 2026-03
Orion EUR 699.6M 270.4M 2026-03
Pfizer USD 16.17B 332M 2026-03
Philips EUR 3.53B 273M 2026-03
Recordati EUR 764.73M 88.12M 2026-03
Regeneron Pharmaceuticals USD 5.73B 10.1M 2026-03
Roche Holding CHF 11.9B 460M 2025-12
Sanofi EUR 482M 85M 2026-03
UCB EUR 1.97B 54M 2025-12